Biomind Labs Inc. announced positive results from in vivo studies. Biomind Labs' BMND07 drug candidate, a novel DMT combination drug, proved to be physiologically safe, showing low acute oral toxicity and no mutagenic effect in all administered dosages in animals.
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
0.11 USD | -.--% | -.--% | +10.00% |
1st Jan change | Capi. | |
---|---|---|
+10.00% | 8.22M | |
+33.37% | 49.46B | |
+1.55% | 42.58B | |
+49.11% | 42.49B | |
-4.22% | 29.09B | |
+11.57% | 26.61B | |
-21.00% | 18.64B | |
+7.36% | 13.16B | |
+28.30% | 12.55B | |
+23.80% | 12.1B |
- Stock Market
- Equities
- BMND.F Stock
- News Biomind Labs Inc.
- Biomind Labs Inc. Announces Positive Results on in Vivo Studies for its Proprietary Drug Candidate BMND07